UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Current status of and future prospects for the treatment of unresectable or metastatic gastrointestinal stromal tumours

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2023-05, Vol.26 (3), p.339-351

2023

Volltextzugriff (PDF)

Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2019-07, Vol.22 (4), p.793-802

2019

Volltextzugriff (PDF)

Immunotherapy for Esophageal Squamous Cell Carcinoma

Current Oncology Reports, 2017-05, Vol.19 (5), p.33-33, Article 33

2017

Volltextzugriff (PDF)

Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein–Barr virus status in a large cohort of gastric cancer patients

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2017-05, Vol.20 (3), p.407-415

2017

Volltextzugriff (PDF)

Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8 + T cells in the tumor microenvironment

Journal for immunotherapy of cancer, 2018-10, Vol.6 (1), p.106-106, Article 106

2018

Volltextzugriff (PDF)

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer

BMC cancer, 2019-03, Vol.19 (1), p.196-196, Article 196

2019

Volltextzugriff (PDF)

Enhanced tumor response to radiotherapy after PD-1 blockade in metastatic gastric cancer

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2020-09, Vol.23 (5), p.893-903

2020

Volltextzugriff (PDF)

Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2019-07, Vol.22 (4), p.828-837

2019

Volltextzugriff (PDF)

Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2015-04, Vol.18 (2), p.227-238

2015

Volltextzugriff (PDF)

Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer

Journal for immunotherapy of cancer, 2019-01, Vol.7 (1), p.24-24, Article 24

2019

Volltextzugriff (PDF)

Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumors

Investigational new drugs, 2020-08, Vol.38 (4), p.1175-1185

2020

Volltextzugriff (PDF)

A phase 1 study of crenigacestat (LY3039478), the Notch inhibitor, in Japanese patients with advanced solid tumors

Investigational new drugs, 2021-04, Vol.39 (2), p.469-476

2021

Volltextzugriff (PDF)

Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS)

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2022-05, Vol.25 (3), p.586-597

2022

Volltextzugriff (PDF)

Phase 1 study of sulfasalazine and cisplatin for patients with CD44v-positive gastric cancer refractory to cisplatin (EPOC1407)

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2017-11, Vol.20 (6), p.1004-1009

2017

Volltextzugriff (PDF)

Efficacy and safety of TAS-115, a novel oral multi-kinase inhibitor, in osteosarcoma: an expansion cohort of a phase I study

Investigational new drugs, 2021-12, Vol.39 (6), p.1559-1567

2021

Volltextzugriff (PDF)

Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2019-07, Vol.22 (4), p.817-827

2019

Volltextzugriff (PDF)

Phase 1 study of napabucasin, a cancer stemness inhibitor, in patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2020-05, Vol.85 (5), p.855-862

2020

Volltextzugriff (PDF)

Dose-escalation study for the targeting of CD44v+ cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205)

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2017-03, Vol.20 (2), p.341-349

2017

Volltextzugriff (PDF)

Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein–Barr virus status, and cancer genome alterations in metastatic gastric cancer

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2019-01, Vol.22 (1), p.69-76

2019

Volltextzugriff (PDF)

Body weight loss as a prognostic and predictive factor in previously treated patients with metastatic gastric cancer: post hoc analyses of the randomized phase III TAGS trial

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2023-07, Vol.26 (4), p.626-637

2023

Volltextzugriff (PDF)

Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2020-07, Vol.23 (4), p.689-698

2020

Volltextzugriff (PDF)

Phase I dose-escalation study of the safety, tolerability, and pharmacokinetics of aflibercept in combination with S-1 in Japanese patients with advanced solid malignancies

Investigational new drugs, 2020-10, Vol.38 (5), p.1390-1399

2020

Volltextzugriff (PDF)

Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2021-07, Vol.24 (4), p.970-977

2021

Volltextzugriff (PDF)

Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer

Investigational new drugs, 2020-12, Vol.38 (6), p.1836-1845

2020

Volltextzugriff (PDF)

A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1–4, as a single dose and multiple doses in patients with solid malignancies

Investigational new drugs, 2020-04, Vol.38 (2), p.445-456

2020

Volltextzugriff (PDF)

1 – 25 von 143

Suche als RSS-Feed

Aktive Filter

KollektionSpringerNature Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(142)
Mit Volltextzugriff
(143)

Publikationsform

Artikel
(142)
Berichte
(1)

Sprache

Englisch
(143)
Japanisch
(31)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

7 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Current status of and future prospects for the treatment of unresectable or metastatic gastrointestinal stromal tumours

Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer

Immunotherapy for Esophageal Squamous Cell Carcinoma

Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein–Barr virus status in a large cohort of gastric cancer patients

Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8 + T cells in the tumor microenvironment

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer

Enhanced tumor response to radiotherapy after PD-1 blockade in metastatic gastric cancer

Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study

Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma

Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer

Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumors

A phase 1 study of crenigacestat (LY3039478), the Notch inhibitor, in Japanese patients with advanced solid tumors

Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS)

Phase 1 study of sulfasalazine and cisplatin for patients with CD44v-positive gastric cancer refractory to cisplatin (EPOC1407)

Efficacy and safety of TAS-115, a novel oral multi-kinase inhibitor, in osteosarcoma: an expansion cohort of a phase I study

Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial

Phase 1 study of napabucasin, a cancer stemness inhibitor, in patients with advanced solid tumors

Dose-escalation study for the targeting of CD44v+ cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205)

Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein–Barr virus status, and cancer genome alterations in metastatic gastric cancer

Body weight loss as a prognostic and predictive factor in previously treated patients with metastatic gastric cancer: post hoc analyses of the randomized phase III TAGS trial

Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS

Phase I dose-escalation study of the safety, tolerability, and pharmacokinetics of aflibercept in combination with S-1 in Japanese patients with advanced solid malignancies

Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study

Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer

A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1–4, as a single dose and multiple doses in patients with solid malignancies

Aktive Filter

Suchergebnisse filtern